Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 5 | 2025 | 124 | 3.330 |
Why?
|
| Ultraviolet Therapy | 2 | 2025 | 15 | 1.670 |
Why?
|
| Calciphylaxis | 7 | 2024 | 17 | 1.650 |
Why?
|
| Dermatology | 4 | 2023 | 74 | 1.610 |
Why?
|
| Cellulitis | 7 | 2022 | 23 | 1.070 |
Why?
|
| Kidney Failure, Chronic | 5 | 2021 | 205 | 0.970 |
Why?
|
| Vision Disorders | 1 | 2025 | 70 | 0.860 |
Why?
|
| Hearing Loss | 1 | 2025 | 55 | 0.830 |
Why?
|
| Visual Acuity | 1 | 2025 | 134 | 0.830 |
Why?
|
| Hypopigmentation | 1 | 2023 | 16 | 0.760 |
Why?
|
| Lasers, Dye | 1 | 2022 | 6 | 0.760 |
Why?
|
| Epidermolysis Bullosa Dystrophica | 1 | 2022 | 15 | 0.750 |
Why?
|
| Soft Tissue Injuries | 1 | 2022 | 21 | 0.740 |
Why?
|
| Child | 9 | 2025 | 4678 | 0.680 |
Why?
|
| Students, Medical | 1 | 2023 | 266 | 0.660 |
Why?
|
| Referral and Consultation | 4 | 2022 | 435 | 0.620 |
Why?
|
| Methotrexate | 2 | 2017 | 83 | 0.620 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 595 | 0.610 |
Why?
|
| Shigella flexneri | 2 | 2018 | 19 | 0.590 |
Why?
|
| Factor Xa Inhibitors | 1 | 2018 | 37 | 0.560 |
Why?
|
| Pyridones | 1 | 2018 | 43 | 0.560 |
Why?
|
| Child, Preschool | 4 | 2025 | 2077 | 0.550 |
Why?
|
| Skin Diseases | 1 | 2019 | 84 | 0.540 |
Why?
|
| Pyrazoles | 1 | 2018 | 90 | 0.540 |
Why?
|
| Graft vs Host Disease | 1 | 2019 | 115 | 0.540 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 114 | 0.530 |
Why?
|
| Folic Acid | 1 | 2017 | 43 | 0.520 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2016 | 8 | 0.490 |
Why?
|
| Host-Pathogen Interactions | 3 | 2018 | 282 | 0.480 |
Why?
|
| Internship and Residency | 1 | 2023 | 815 | 0.470 |
Why?
|
| Retrospective Studies | 11 | 2025 | 6882 | 0.450 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 383 | 0.450 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2015 | 19 | 0.450 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 47 | 0.440 |
Why?
|
| GTPase-Activating Proteins | 1 | 2015 | 69 | 0.430 |
Why?
|
| Virulence Factors | 1 | 2015 | 85 | 0.430 |
Why?
|
| Humans | 33 | 2025 | 65528 | 0.420 |
Why?
|
| Endocytosis | 1 | 2015 | 153 | 0.420 |
Why?
|
| Adolescent | 5 | 2025 | 6383 | 0.410 |
Why?
|
| Case-Control Studies | 3 | 2025 | 1157 | 0.390 |
Why?
|
| Bacterial Proteins | 2 | 2018 | 784 | 0.390 |
Why?
|
| Patch Tests | 2 | 2020 | 12 | 0.340 |
Why?
|
| Dermatitis, Allergic Contact | 2 | 2020 | 13 | 0.330 |
Why?
|
| Allergens | 2 | 2020 | 57 | 0.330 |
Why?
|
| Male | 13 | 2025 | 31073 | 0.320 |
Why?
|
| Vascular Diseases | 2 | 2021 | 83 | 0.320 |
Why?
|
| Phototherapy | 2 | 2023 | 36 | 0.310 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 872 | 0.310 |
Why?
|
| Home Care Services | 2 | 2020 | 99 | 0.300 |
Why?
|
| Female | 13 | 2025 | 34125 | 0.300 |
Why?
|
| Blood Culture | 2 | 2018 | 10 | 0.290 |
Why?
|
| Insulin Infusion Systems | 1 | 2025 | 11 | 0.240 |
Why?
|
| Granuloma | 1 | 2025 | 44 | 0.230 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2025 | 8 | 0.230 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2025 | 29 | 0.230 |
Why?
|
| Epigenomics | 1 | 2025 | 63 | 0.220 |
Why?
|
| Delayed Diagnosis | 1 | 2024 | 48 | 0.210 |
Why?
|
| Dermatologists | 1 | 2023 | 13 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 1 | 2025 | 200 | 0.200 |
Why?
|
| Hypoglycemic Agents | 1 | 2025 | 224 | 0.200 |
Why?
|
| Collagen Type VII | 1 | 2022 | 5 | 0.190 |
Why?
|
| Erythema | 1 | 2022 | 12 | 0.190 |
Why?
|
| Blister | 1 | 2022 | 16 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 143 | 0.180 |
Why?
|
| Recurrence | 1 | 2024 | 660 | 0.180 |
Why?
|
| Insulin | 1 | 2025 | 693 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 407 | 0.180 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 438 | 0.180 |
Why?
|
| Incidence | 1 | 2025 | 1410 | 0.170 |
Why?
|
| Vascular Malformations | 1 | 2021 | 22 | 0.170 |
Why?
|
| Thiosulfates | 1 | 2020 | 3 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2025 | 632 | 0.160 |
Why?
|
| Heart Murmurs | 1 | 2020 | 5 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2025 | 413 | 0.160 |
Why?
|
| Sarcoma, Myeloid | 1 | 2020 | 3 | 0.160 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2020 | 15 | 0.160 |
Why?
|
| Quality of Life | 2 | 2025 | 1271 | 0.160 |
Why?
|
| Treatment Outcome | 2 | 2023 | 5819 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2020 | 39 | 0.150 |
Why?
|
| Skin | 1 | 2022 | 425 | 0.150 |
Why?
|
| Middle Aged | 7 | 2024 | 18266 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 3 | 2020 | 822 | 0.140 |
Why?
|
| Type III Secretion Systems | 1 | 2018 | 4 | 0.140 |
Why?
|
| Dysentery, Bacillary | 1 | 2018 | 14 | 0.140 |
Why?
|
| Skin Temperature | 1 | 2017 | 19 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 193 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 2018 | 195 | 0.130 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2783 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2018 | 280 | 0.120 |
Why?
|
| Mutation | 1 | 2025 | 2679 | 0.120 |
Why?
|
| Retinoids | 1 | 2016 | 12 | 0.120 |
Why?
|
| Dapsone | 1 | 2016 | 10 | 0.120 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 23 | 0.120 |
Why?
|
| Kidney Diseases | 1 | 2018 | 180 | 0.120 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 20 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2018 | 418 | 0.120 |
Why?
|
| Thalidomide | 1 | 2016 | 34 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 473 | 0.120 |
Why?
|
| Laser Therapy | 1 | 2016 | 42 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2019 | 358 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2019 | 761 | 0.120 |
Why?
|
| Adult | 7 | 2024 | 17418 | 0.120 |
Why?
|
| Aged | 6 | 2024 | 14946 | 0.110 |
Why?
|
| Phosphatidylinositols | 1 | 2015 | 52 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2016 | 182 | 0.110 |
Why?
|
| Infant | 1 | 2019 | 1718 | 0.100 |
Why?
|
| HeLa Cells | 1 | 2015 | 550 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2018 | 721 | 0.100 |
Why?
|
| Risk Factors | 4 | 2024 | 5442 | 0.090 |
Why?
|
| Bacterial Infections | 1 | 2013 | 155 | 0.090 |
Why?
|
| Age Factors | 3 | 2020 | 1593 | 0.090 |
Why?
|
| Time Factors | 1 | 2019 | 3789 | 0.090 |
Why?
|
| Autophagy | 1 | 2013 | 236 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2016 | 558 | 0.080 |
Why?
|
| Bacteria | 1 | 2013 | 338 | 0.080 |
Why?
|
| Patient Preference | 2 | 2020 | 88 | 0.080 |
Why?
|
| Models, Biological | 1 | 2015 | 1217 | 0.080 |
Why?
|
| Young Adult | 1 | 2019 | 4836 | 0.070 |
Why?
|
| Lower Extremity | 2 | 2021 | 162 | 0.070 |
Why?
|
| Hospitals | 2 | 2020 | 391 | 0.070 |
Why?
|
| Immunity, Innate | 1 | 2013 | 816 | 0.060 |
Why?
|
| Benzamides | 1 | 2025 | 69 | 0.060 |
Why?
|
| Forkhead Transcription Factors | 1 | 2025 | 133 | 0.050 |
Why?
|
| Pyridines | 1 | 2025 | 117 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2025 | 146 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 267 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2025 | 270 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 593 | 0.040 |
Why?
|
| Dermatitis, Irritant | 1 | 2020 | 4 | 0.040 |
Why?
|
| Symptom Flare Up | 1 | 2020 | 16 | 0.040 |
Why?
|
| Body Size | 1 | 2020 | 24 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 79 | 0.040 |
Why?
|
| Dermatitis, Atopic | 1 | 2020 | 33 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 68 | 0.040 |
Why?
|
| Veins | 1 | 2021 | 64 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 1611 | 0.040 |
Why?
|
| Chelating Agents | 1 | 2020 | 51 | 0.040 |
Why?
|
| Office Visits | 1 | 2020 | 49 | 0.040 |
Why?
|
| Penis | 1 | 2020 | 38 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 125 | 0.040 |
Why?
|
| Prevalence | 1 | 2024 | 1441 | 0.040 |
Why?
|
| Judgment | 1 | 2018 | 36 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2018 | 9 | 0.030 |
Why?
|
| Unnecessary Procedures | 1 | 2018 | 50 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2018 | 37 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2018 | 75 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 998 | 0.030 |
Why?
|
| Standard of Care | 1 | 2017 | 28 | 0.030 |
Why?
|
| Upper Extremity | 1 | 2018 | 54 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 301 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 95 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 137 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 207 | 0.030 |
Why?
|
| Caregivers | 1 | 2020 | 291 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2018 | 316 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2018 | 284 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 494 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 314 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 906 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 271 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3355 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 996 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 1114 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 831 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 877 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1282 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1145 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1286 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 738 | 0.030 |
Why?
|
| Cell Line | 1 | 2018 | 2071 | 0.030 |
Why?
|
| Bacterial Secretion Systems | 1 | 2013 | 11 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 1650 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1576 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2511 | 0.020 |
Why?
|
| Macrophages | 1 | 2018 | 1059 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2013 | 266 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 2635 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 11215 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2101 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2013 | 278 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 923 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 21529 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1186 | 0.020 |
Why?
|